培门冬酶与左旋门冬酰胺酶治疗Ph阴性急性淋巴细胞白血病的对比研究

Abstract
Figure/Table
References (21)
Related Citation (0)

Download: PDF (676 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To compare the efficacy and security between pegaspargase and L-asparaginase in the treatment of Ph-negative acute lymphoblastic leukemia. Methods Clinical data of 52 Ph-negative acute lymphoblastic leukemia cases admitted to the First People′s Hospital of Lianyungang from January 2007 to March 2018 were retrospectively analyzed. All the cases received VDCLP chemotherapy and were divided into the pegaspargase group (25 cases) and the L-asparaginase group (27 cases). The efficacy, adverse reactions and survival status between the two groups were compared. Results The general information between the two groups were homogeneous, there was no statistically significant difference (P ＞ 0.05). There was no statistically significant difference in the total effective rate between the two groups (P ＞ 0.05). The incidence of allergic reactions and hyperglycemia in the L-asparaginase group was higher than that in the pegaspargase group (P ＜ 0.05). The minimum value of fibrinogen (FIB) in the pegaspargase group was bigger than the L-asparaginase group, and the duration rise time of activated partial thromboplastin time in the pegaspargase group was shorter than the L-asparaginase group (P ＜ 0.05). Conclusion Pegaspargase is effective and safe in the treatment of Ph-negative acute lymphoblastic leukemia and it is worth of clinical promotion.

Key words： Ph-negative Acute Lymphoblastic Leukemia Pegaspargase L-asparaginase

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIA Tao WANG Ying ZHU Yuanxin MAO Jianping XUE Lianguo WEI Jifeng CHEN Ze ZHAO Lidong

Cite this article:

JIA Tao WANG Ying ZHU Yuanxin MAO Jianping XUE Lianguo WEI Jifeng CHEN Ze ZHAO Lidong. Comparison of efficacy and security between pegaspargase and L-asparaginase in treatment of Ph-negative acute lymphoblastic leukemia[J]. 中国医药导报, 2018, 15(26): 117-120.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I26/117

[1] Rowe JM，Buck G，Burnett AK，et al. Induction therapy for adults with acute lymphoblastic leukemia：results of more than 1500 patients from the international ALL trial：MRC UKALL XII/ECOG E2993 [J]. Blood，2005，106（12）：3760-3767.
[2] 王宇阳，赵京，师晓东，等.阿糖胞苷联合VDLD方案诱导治疗儿童难治/复发急性淋巴细胞白血病的临床观察[J].中国医药导报，2017，14（5）：71-74.
[3] 贾韬，陈泽，刘惠杰，等.老年急性白血病30例临床分析[J].基层医学论坛，2014，18（28）：3817-3819.
[4] 谭玮玮，赵国祥.达沙替尼在Ph阳性急性淋巴细胞白血病中的应用及疗效观察[J].中国社区医师，2018，34（8）：55，57.
[5] Liu-Dumlao T，Kantarjian H，Thomas DA，et al. Philadelphia-positive acute lymphoblastic leukemia：current treatment options [J]. Curr Oncol Rep，2012，14（5）：387-394.
[6] Chiaretti S，Vitale A，Vignetti M，et al. A sequential approach with imatinib，chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia：final results of the GIMEMA LAL 0904 study [J]. Haematologica，2016，101（12）：1544-1552.
[7] 张孝平，陈宝安，葛峥，等.61例成人急性淋巴细胞白血病患者的临床特征和疗效分析[J].中国实验血液学杂志，2017，25（3）：711-717.
[8] 高泓浩，靖彧，于力.Ph阴性青少年与年轻成人急性淋巴细胞白血病预后及治疗综述[J].解放军医学院学报，2017，38（4）：389-392.
[9] Salzer W，Seibel N，Smith M. Erwinia asparaginase in pediatric acute lymphoblastic leukemia [J]. Expert Opin Biol Ther，2012，12（10）：1407-1414.
[10] Masetti R，Pession A. First-line treatment of acute lymphoblastic leukemia with pegasparaginase [J]. Biologics，2009，3：359-368.
[11] Bleyer A，Asselin BL，Koontz SE，et al. Clinical application of asparaginase activity levels following treatment with pegaspargase [J]. Pediatr Blood Cancer，2015，62（6）：1102-1105.
[12] Henriksen LT，Harila-Saari A，Ruud E，et al. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHOALL2008 protocol [J]. Pediatr Blood Cancer，2015，62（3）：427-433.
[13] Stock W，Douer D，DeAngelo DJ，et al． Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents：recommendations of an expert panel [J]. Leuk Lymphoma，2011，52（12）：2237-2253.
[14] 王艳春，陶蕾.左旋门冬酰胺酶在儿童急性淋巴细胞白血病临床应用的安全性分析[J].药物评价研究，2012， 35（4）：285-288.
[15] 皋文君，刘砚燕，袁长蓉.国际肿瘤化疗药物不良反应评价系统—通用不良反应术语标准4.0版[J].肿瘤，2012， 32（2）：142-144.
[16] Graham ML. Pegaspargase：a review of clinical studies [J]. Adv Drug Deliv Rev，2003，55（10）：1293-1302.
[17] Stock W，Douer D，DeAngelo DJ，et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents：recommendations of an expert panel [J]. Leuk Lymphoma，2011，52（12）：2237-2253.
[18] Piatkowska-Jakubas B，Krawczyk-Kulis M，Giebel S，et al. Use of L-asparaginase in acute lymphoblastic leukemia： recommendations of the Polish Adult Leukemia Group [J]. Pol Arch Med Wewn，2008，118（11）：664-669.
[19] Reyes VE Jr，Al-Saleem T，Robu VG，et al. Extranodal NK/T-cell lymphoma nasal type：efficacy of Pegasparaginase． Report of two patients from the united sates and review of literature [J]. Leuk Res，2010，34（1）：e50-e54.
[20] Ranta S，Heyman MM，Jahnukajnen K，et al. Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia [J]. Blood Coagul Fibrinolysis，2013，24（7）：749-756.
[21] Ping LY，Zheng W，Wang XP，et al. Safety and adverse event profiling of pegylated L-asparaginase combined chemotherapy in the treatment of lymphoma [J]. Zhonghua Yi Xue Za Zhi，2012，92（46）：3257-3260.